The relative risk of ischemic cerebrovascular accident in patients with Von Willebrand disease. (April 2023)

• Record Type: Journal Article
• Authors: Olagunju, Abdulbaril; Mihyawi, Nawfal; Fath, Ayman R; Bhattarai, Bikash; Eldaly, Abdullah S; Forst, Beani; Mantha, Yogamaya; Yeneneh, Beeletsega T
• Is Part Of: Journal of investigative medicine. Volume 71:Number 4(2023)
• Page Start: 394
• Page End: 399
• Publication Date: 2023-04
• Subjects: Von Willebrand disease -- ischemic stroke -- endothelium -- smoking -- blood group O; Clinical medicine -- Periodicals; Medicine -- Research -- Periodicals; Medicine; Research -- United States; Clinical medicine; Medicine -- Research; Periodicals; 616.075
• DOI: 10.1177/10815589221150642
• Languages: English
• ISSNs: 1081-5589

Abstract

Cerebrovascular accident (CVA) is one of the leading causes of death in the United States. Von Willebrand factor plays an important role in platelet activation and adhesion. It remains unclear whether Von Willebrand disease (vWD) is associated with a decreased risk of developing CVA. The study aimed to compare the relative risk (RR) of CVA in patients with and without vWD. We queried the National Inpatient Sample from 2009 to 2014 for discharge data and records for vWD and CVA using International Classification of Diseases, Ninth-Revision codes. The unadjusted and adjusted RR of CVA in patients with and without vWD were estimated using log-binomial model. Descriptive measures including means, medians, standard deviations, and range were presented based on normality test of continuous data. The prevalence of CVA was lower in patients with vWD than in those without vWD (1.31% vs 2.04%), with a RR of 0.64 (95% confidence interval (CI): 0.60–0.68). After adjusting for common CVA risk factors, the RR remained lower in vWD patients: 0.81 (95% CI: 0.76–0.86). vWD is associated with a lower RR of developing CVA. This suggests that deficiency of Von Willebrand factor is potentially protective against the development of CVA. To the best of our knowledge, this is the first study in humans to compare the RR of CVA in patients with and without vWD. Future studies are needed to explore causal relationships and therapeutic benefits.